Russian developers of Sputnik V plan to produce 850 mn doses a year in India

0
83

Dr. Reddy has the right to the distribution of the first 100 million doses in India, which will be a combination of Indian and Russian vaccines

Vials of the Sputnik V Covid-19 vaccine.
Vials of the Sputnik V Covid-19 vaccine.

Russian developers from Sputnik V Covid-19 vaccine, which have been given approval by Indian drug controllers for emergency use, has been tied with several Indian pharmaceutical companies to produce more than 850 million doses per year.

Developers – National Gamealya Research Center for Epidemiology and Microbiology Named and Russia Direct Investment Fund (RDIF) – Initially tied with DR Reddy laboratories for trials, regulatory approval and vaccine distribution.

Dr. Reddy has the right to the distribution of the first 100 million doses in India,

which will be a combination of Indian and Russian vaccines. Since March, developers have sew more agreements to increase vaccine production in India.

These include agreements with Gland Pharma, Hetero Biopharma, Panacea Biotec, Stasis Biopharma and Virchow Biotech aimed at production of more than 850 million doses per year.

Medication Controller of the Indian General (DCGI) on Tuesday approved the use of Sputnik V emergency against the Coronavirus in the country after a subject expert committee recommended that there was enough data to support that this vaccine was suitable for use.

Also Watch | Covid: From April 15, meals only on flights with journey time of 2 hours or more

India became the 60th country to approve Sputnik V, which is one of the three coronavirus vaccines registered by Indian Supervisory Authorities. India is also the most populous country to register the Russian vaccine.

Other countries that have approved the Russian vaccine including Venezuela, Paraguay, United Arab Emirates, Iran, Mexico, Pakistan, Bahrain, Egypt, Sri Lanka, Iraq, Philippines, Camerapi and Mauritius.

CEO of RDIF Kirill Dmitriev said:

“We appreciate the decision of the Indian Regulatory Agency to provide authorization for Sputnik V. Vaccine approval is a major milestone such as Russia and India has developed extensive cooperation regarding Sputnik V clinical trials in India and Its local production.”

He added, “India is a vaccine manufacturing hub and our strategic partners for the production of Sputnik V. RDIF has created a partnership with a number of leading Indian pharmaceutical companies for Sputnik V production that will provide population vaccination in India and the global distribution of Russian vaccines.”

Collaboration on the Covid-19 vaccine has also found out in a recent meeting between the Minister of External Affairs S Jaishankar and his Russian colleague Sergey Lavrov, who recorded RDIF has signed a contract with Indian companies to produce Sputnik Vacine V. He did not rule out further cooperation to cover Manufacture of Indian vaccines in Russia.

LEAVE A REPLY

Please enter your comment!
Please enter your name here